Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 26, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
The filing details the following specific transactions regarding directors' interests:
- August 21, 2003: The GlaxoSmithKline Employee Trust (GSK Trust) transferred 8,090 Ordinary Shares to a participant in the Glaxo Wellcome 1999 Long Term Incentive Plan.
- August 22, 2003: The GSK Trust transferred 2,243 Ordinary Shares to a participant in the Glaxo Wellcome 1999 Long Term Incentive Plan.
- August 21, 2003: The GlaxoSmithKline US Retirement Savings Plan increased its holdings of Ordinary Share ADRs from 18,990,876 to 18,993,746 at an average price of $38.93.
Directors Dr. J-P Garnier and Mr. J D Coombe are noted as having interests in the GSK Trust, while Dr. J-P Garnier has a potential interest in the US Retirement Savings Plan, consistent with their status as employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of share movements.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust and the US Retirement Savings Plan to assess the scale of these transactions relative to total holdings.
- Confirm the specific identity of the incentive plan participants receiving the transferred shares.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K filing contains no financial metrics.